Jpmorgan Chase & CO Kiniksa Pharmaceuticals, Ltd. Transaction History

Jpmorgan Chase & CO

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Dec 26, 2024	BUY	$17.63 - $21.74 $391,121 - $482,301	22,185 New	22,185 $437,000
Q1 2024 May 10, 2024	SELL	$17.63 - $21.74 $419,329 - $517,085	-23,785 Reduced 51.74%	22,185 $437,000
Q4 2023 Dec 26, 2024	BUY	$14.37 - $19.07 $660,588 - $876,647	45,970 New	45,970 $806,000
Q4 2023 Feb 12, 2024	BUY	$14.37 - $19.07 $253,932 - $336,985	17,671 Added 62.44%	45,970 $806,000
Q3 2023 Nov 14, 2023	BUY	$13.62 - $20.2 $36,487 - $54,115	2,679 Added 10.46%	28,299 $491,000
Q2 2023 Aug 11, 2023	BUY	$10.44 - $16.48 $615 - $972	59 Added 0.23%	25,620 $360,000
Q1 2023 May 18, 2023	BUY	$10.7 - $15.79 $255,355 - $376,828	23,865 Added 1407.13%	25,561 $275,000
Q1 2023 May 11, 2023	SELL	$10.7 - $15.79 $193,980 - $286,256	-18,129 Reduced 91.45%	1,696 $18,000
Q4 2022 Feb 13, 2023	BUY	$11.42 - $17.05 $6,132 - $9,155	537 Added 2.78%	19,825 $297,000
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $10,882 - $14,952	1,115 Added 6.14%	19,288 $248,000
Q2 2022 Aug 11, 2022	BUY	$7.6 - $11.41 $2,644 - $3,970	348 Added 1.95%	18,173 $175,000
Q1 2022 May 11, 2022	BUY	$9.3 - $12.37 $31,908 - $42,441	3,431 Added 23.84%	17,825 $177,000
Q4 2021 Feb 10, 2022	BUY	$10.39 - $15.15 $12,748 - $18,589	1,227 Added 9.32%	14,394 $169,000
Q3 2021 Nov 12, 2021	BUY	$11.39 - $16.23 $149,972 - $213,700	13,167 New	13,167 $149,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.